-
-
-
Kumar et al set out to describe the cost of ICU telemedicine programs (tele-ICU). They had two objectives: to systematically review the existing literature reporting costs of tele-ICU programs and to provide cost figures for tele-ICU implementation in a Veterans Health Administration (VHA) hospital network.
-
Goldberger and colleagues at the University of Michigan sought to determine the variation in duration of cardiopulmonary resuscitation (CPR) attempts following in-hospital cardiac arrest among different institutions across the United States.
-
In this issue: Side effects of statins; effects of cannabis use; antihypertensives and lip cancer; and FDA actions.
-
-
Response rates for patients with hairy cell leukemia are high and typically of long duration, yet one-third or more will relapse. The use of oral fludarabine in combination with rituximab in four monthly cycles was shown to be highly effective in reinducing durable remissions.
-
A 48-year-old woman, who is 8 years post-hysterectomy for excessive menstrual bleeding, just completed a four-cycle course of chemotherapy (doxorubicin and cyclophosphamide), for a 2.8 cm, high-grade breast cancer with a negative sentinel node biopsy.
-
In this Phase 2 trial, 32 heavily pretreated patients including those who received adjuvant temozolamide, were treated with daily low-dose temozolamide at 50 mg/m2 and twice-weekly Bevacizumab. The treatment was well tolerated with a median progression-free survival of 15.8 weeks and a median overall survival of 37 weeks. However, this was lower than those reported in studies with single-agent bevacizumab and bevacizumab/irinotecan combination.
-
In a Phase 3 trial including 268 patients with advanced biliary tract cancers, response rates were improved in patients receiving erlotinib with chemotherapy (gemcitabine/oxaliplatin) compared to chemotherapy alone. However, progression-free survival was not enhanced except for the subset with cholangiocarcinoma.
